Arvinas (ARVN) Non-Current Deffered Revenue (2017 - 2026)
Arvinas (ARVN) recorded quarterly Non-Current Deffered Revenue of $138.2 million in Q1 2026, up 2.9% quarter-over-quarter from $134.3 million in Q4 2025, and up 16.72% on a YoY basis from $118.4 million in Q1 2025.
Arvinas (ARVN) Non-Current Deffered Revenue (2017 - 2026) Analysis & Trends
Arvinas' Non-Current Deffered Revenue history runs 10 years deep, the most recent figure standing at $138.2 million for Q1 2026.
- In Q1 2026, Non-Current Deffered Revenue rose 16.72% year-over-year to $138.2 million; the TTM figure through Mar 2026 stood at $138.2 million (up 16.72% YoY), while the FY2025 annual figure was $134.3 million, down 54.01% from the prior year.
- Non-Current Deffered Revenue was $138.2 million for Q1 2026 at Arvinas, up from $134.3 million in the prior quarter.
- In the past five years, Non-Current Deffered Revenue ranged from a high of $521.9 million in Q1 2022 to a low of $118.4 million in Q1 2025.
- Historically, Non-Current Deffered Revenue has averaged $304.9 million across 5 years, with a median of $310.5 million in 2023.
- The sharpest annual moves came in 2022 and 2025: Non-Current Deffered Revenue surged 3221.04% in 2022, then tumbled 67.2% in 2025.
- A 5-year view of Non-Current Deffered Revenue shows it stood at $405.1 million in 2022, then decreased by 4.67% to $386.2 million in 2023, then retreated by 24.39% to $292.0 million in 2024, then sank by 54.01% to $134.3 million in 2025, then rose by 2.9% to $138.2 million in 2026.
- The last three Non-Current Deffered Revenue figures came in at $138.2 million (Q1 2026), $134.3 million (Q4 2025), and $127.4 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Arvinas | 492.16 Mn | -122.74 Mn | - | 138.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 138.20 Mn |
| Dec 31, 2025 | 134.30 Mn |
| Sep 30, 2025 | 127.40 Mn |
| Jun 30, 2025 | 134.10 Mn |
| Mar 31, 2025 | 118.40 Mn |
| Dec 31, 2024 | 292.00 Mn |
| Sep 30, 2024 | 304.50 Mn |
| Jun 30, 2024 | 331.30 Mn |
| Mar 31, 2024 | 361.00 Mn |
| Dec 31, 2023 | 386.20 Mn |
| Sep 30, 2023 | 281.90 Mn |
| Jun 30, 2023 | 310.50 Mn |
| Mar 31, 2023 | 378.90 Mn |
| Dec 31, 2022 | 405.10 Mn |
| Sep 30, 2022 | 464.60 Mn |
| Jun 30, 2022 | 493.60 Mn |
| Mar 31, 2022 | 521.90 Mn |
| Dec 31, 2021 | 534.30 Mn |
| Sep 30, 2021 | 600.43 Mn |
| Jun 30, 2021 | 14.86 Mn |